Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - lacosamide
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp3259b4ec962bd839a6862c2a3f8b465b
identifier: http://ema.europa.eu/identifier
/EU/1/19/1383/004
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Lacosamide UCB 50 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-3259b4ec962bd839a6862c2a3f8b465b
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/19/1383/004
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - lacosamide
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
What Lacosamide UCB is Lacosamide UCB contains lacosamide. This belongs to a group of medicines called antiepileptic medicines . These medicines are used to treat epilepsy.
What Lacosamide UCB is used for
Do not take Lacosamide UCB
Do not take Lacosamide UCB if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking this medicine.
Warnings and precautions Talk to your doctor before taking Lacosamide UCB if:
Children Lacosamide UCB is not recommended for children aged under 2 years with epilepsy characterised by the occurrence of partial-onset seizure and not recommended for children aged under 4 years with primary generalised tonic-clonic seizures. This is because we do not yet know whether it will work and whether it is safe for children in this age group.
Other medicines and Lacosamide UCB Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
In particular, tell your doctor or pharmacist if you are taking any of the following medicines that affect your heart - this is because Lacosamide UCB can also affect your heart:
Also tell your doctor or pharmacist if you are taking any of the following medicines - this is because they may increase or decrease the effect of Lacosamide UCB on your body:
Lacosamide UCB with alcohol As a safety precaution do not take Lacosamide UCB with alcohol.
Pregnancy and breast-feeding Fertile women should discuss the use of contraceptives with the doctor.
If you are pregnant or breast-feeding, think you may be pregnant or planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. It is not recommended to take Lacosamide UCB if you are pregnant, as the effects of Lacosamide UCB on pregnancy and the unborn baby are not known.
It is not recommended to breast-feed your baby while taking Lacosamide UCB, as Lacosamide UCB passes into breast milk. Seek advice immediately from your doctor if you get pregnant or are planning to become pregnant. They will help you decide if you should take Lacosamide UCB or not.
Do not stop treatment without talking to your doctor first as this could increase your fits (seizures). A worsening of your disease can also harm your baby.
Driving and using machines Do not drive, cycle or use any tools or machines until you know how this medicine affects you. This is because Lacosamide UCB may make you feel dizzy or cause blurred vision.
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Other form(s) of this medicine may be more suitable for children; ask your doctor or pharmacist.
Taking Lacosamide UCB
You will usually start by taking a low dose each day and your doctor will slowly increase this over a number of weeks. When you reach the dose that works for you, this is called the maintenance dose , you then take the same amount each day. Lacosamide UCB is used as a long term treatment. You should continue to take Lacosamide UCB until your doctor tells you to stop.
How much to take Listed below are the normal recommended doses of Lacosamide UCB for different age groups and weights. Your doctor may prescribe a different dose if you have problems with your kidneys or with your liver.
Adolescents and children weighing 50 kg or more and adults When you take Lacosamide UCB on its own
When you take Lacosamide UCB with other antiepileptic medicines
Children and adolescents weighing less than 50 kg
In the treatment of partial-onset seizure: Observe that Lacosamide UCB is not recommended for children under 2 years of age.
In the treatment of primary generalised tonic-clonic seizures: Observe that Lacosamide UCB is not recommended for children under 4 years of age.
The dose depends on their body weight. They usually start treatment with the syrup and only change to tablets if they are able to take tablets and get the correct dose with the different tablet strengths. The doctor will prescribe the formulation that is best suited to them.
If you take more Lacosamide UCB than you should
If you have taken more Lacosamide UCB than you should, contact your doctor immediately. Do not try to drive. You may experience:
If you forget to take Lacosamide UCB
If you stop taking Lacosamide UCB
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Nervous system side effects such as dizziness may be higher after a single loading dose.
Talk to your doctor or pharmacist if you get any of the following:
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Not known: frequency cannot be estimated from available data
Additional side effects in children
The additional side effects in children were fever (pyrexia), runny nose (nasopharyngitis), sore throat (pharyngitis), eating less than usual (decreased appetite), changes in behaviour, not acting like themselves (abnormal behavior) and lacking in energy (lethargy). Feeling sleepy (somnolence) is a very common side effect in children and may affect more than 1 in 10 children.
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Lacosamide UCB contains
The active substance is lacosamide. One tablet of Lacosamide UCB 50 mg contains 50 mg lacosamide. One tablet of Lacosamide UCB 100 mg contains 100 mg lacosamide. One tablet of Lacosamide UCB 150 mg contains 150 mg lacosamide. One tablet of Lacosamide UCB 200 mg contains 200 mg lacosamide.
The other ingredients are: Tablet core: microcrystalline cellulose, hydroxypropylcellulose, hydroxypropylcellulose (low substituted), colloidal anhydrous silica, crospovidone (polyplasdone XL-10 Pharmaceutical Grade), magnesium stearate. Film-coat: polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide (E171), colourants*.
The colourants are: 50 mg tablet: red iron oxide (E172), black iron oxide (E172), indigo carmine aluminium lake (E132). 100 mg tablet: yellow iron oxide (E172). 150 mg tablet: yellow iron oxide (E172), red iron oxide (E172), black iron oxide (E172). 200 mg tablet: indigo carmine aluminium lake (E132).
What Lacosamide UCB looks like and contents of the pack
Lacosamide UCB is available in packs of 14, 28, 56, 14 x 1 and 56 x 1 film-coated tablets. Lacosamide UCB 50 mg and Lacosamide UCB 100 mg are available in packs of 168 film-coated tablets and Lacosamide UCB 150 mg and Lacosamide UCB 200 mg are available in multipacks comprising 3 cartons, each containing 56 tablets. The 14 x 1 and 56 x 1 film-coated tablets packs are available as perforated unit dose PVC/PVDC blisters sealed with an aluminium foil, all other packs are available with standard PVC/PVDC blisters sealed with an aluminium foil. Not all pack sizes may be marketed.
Marketing Authorisation Holder UCB Pharma S.A., All e de la Recherche 60, B-1070 Bruxelles, Belgium.
Manufacturer UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l Alleud, Belgium. or
Aesica Pharmaceuticals GmbH, Alfred-Nobel Strasse 10, D-40789 Monheim am Rhein, Germany.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.
Belgi /Belgique/Belgien UCB Pharma SA/NV T l/Tel: + 32 / (0)2 559 92 Lietuva UCB Pharma Oy Finland Tel: + 358 9 2514 4221 (Suomija)
Te .: + 359 (0) 2 962 30 Luxembourg/Luxemburg UCB Pharma SA/NV T l/Tel: + 32 / (0)2 559 92 00 (Belgique/Belgien)
esk republika UCB s.r.o. Tel: + 420 221 773 Magyarorsz g UCB Magyarorsz g Kft. Tel.: + 36-(1) 391 0Danmark UCB Nordic A/S Tlf: + 45 / 32 46 24 Malta Pharmasud Ltd. Tel: + 356 / 21 37 64 Deutschland UCB Pharma GmbH Tel: + 49 /(0) 2173 48 4Nederland UCB Pharma B.V. Tel.: + 31 / (0)76-573 11 Eesti UCB Pharma Oy Finland
Tel: + 358 9 2514 4221 (Soome)
Norge UCB Nordic A/S Tlf: + 47 / 67 16 5
UCB . .
: + 30 / 2109974 sterreich UCB Pharma GmbH Tel: + 43 (0)1 291 80 Espa a UCB Pharma, S.A. Tel: + 34 / 91 570 34 Polska UCB Pharma Sp. z o.o. / VEDIM Sp. z o.o. Tel: + 48 22 696 99 France UCB Pharma S.A. T l: + 33 / (0)1 47 29 44 Portugal UCB Pharma (Produtos Farmac uticos), Lda
Tel: + 351 21 302 5Hrvatska Medis Adria d.o.o. Tel: +385 (0) 1 230 34 Rom nia UCB Pharma Romania S.R.L. Tel: + 40 21 300 29 Ireland UCB (Pharma) Ireland Ltd. Tel: + 353 / (0)1-46 37 Slovenija Medis, d.o.o. Tel: + 386 1 589 69 sland Vistor hf. Simi: + 354 535 7Slovensk republika UCB s.r.o., organiza n zlo ka Tel: + 421 (0) 2 5920 2Italia UCB Pharma S.p.A. Tel: + 39 / 02 300 Suomi/Finland UCB Pharma Oy Finland Puh/Tel: + 358 9 2514 4
Lifepharma (Z.A.M.) Ltd : + 357 22 05 63 Sverige UCB Nordic A/S Tel: + 46 / (0) 40 29 49 Latvija UCB Pharma Oy Finland Tel: + 358 9 2514 4221 (Somija)
United Kingdom (Northern Ireland) UCB (Pharma) Ireland Ltd. Tel: + 353 / (0)1-46 37 This leaflet was last revised in {month/YYYY}.
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-3259b4ec962bd839a6862c2a3f8b465b
Resource Composition:
Generated Narrative: Composition composition-en-3259b4ec962bd839a6862c2a3f8b465b
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/19/1383/004status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - lacosamide
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp3259b4ec962bd839a6862c2a3f8b465b
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp3259b4ec962bd839a6862c2a3f8b465b
identifier:
http://ema.europa.eu/identifier
/EU/1/19/1383/004type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Lacosamide UCB 50 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en